Back

Latest Forum Topics / Raffles Medical    Last:0.86 --

Post Reply

Vicom Post Reply Rate topic
tongphlp Supreme	05-Aug-2026 16:38        tongphlp About Contact  Quote this Post!
x 0   x 0  Alert Admin	woo hoo Joelton      ( Date: 03-Aug-2026 09:10) Posted: Raffles Medical Group marks 50th anniversary Raffles Medical Group has marked its 50th anniversary, adding a milestone from the initial two-clinic practice to a regional healthcare group today that operates in 12 cities in five Asian countries. Besides its four hospitals, RMG runs over 100 multi-disciplinary clinics, offering services such as health screening, specialist care, diagnostic radiology, dental and traditional Chinese medicine. &ldquo When Dr Alfred Loh and I started a two-clinic practice, we simply wanted to care for our patients well. That conviction has remained at the heart of RafflesMedicalGroup through every moment that shaped us and every challenge we overcame," says executive chairman Dr Loo Choon Yong. " Our journey has been made possible by the dedication of our people, the trust of our patients and the support of our partners and communities," he adds. To mark this occasion, the company announced a five-year $5 million commitment to increase access to healthcare and education, advance healthy longevity research and support vulnerable communities. RMG will also award 50 scholarships over the next five years for students from Singapore and the region pursuing healthcare-related studies. The announcements were made at RMG&rsquo s 50th anniversary dinner, graced by President Tharman Shanmugaratnam, and Ong Ye Kung, Minister for Health and Coordinating Minister for Social Policies. According to RMG, the $5 million will focus on four priority areas: increasing access to healthcare, supporting education, advancing healthy longevity research, and uplifting vulnerable communities. One of the first initiatives under the commitment is a two-year partnership with Children&rsquo s Aid, formerly known as Children&rsquo s Aid Society. Over the next two years, RMG will partner CAL to make specialised care more accessible to children and youths who have experienced adverse life circumstances and are under the residential care of Melrose Home, with therapeutic and counselling services under Melrose Care, to support healing, healthy development and long-term well-being. Via the scholarship programme, RMG aims to develop healthcare talent across the cities in which it operates and nurture the next generation of professionals and leaders who will shape the future of healthcare. Since 2012, RMG has provided 51 scholarships to Singaporeans and others in the region.
Useful To Me  Not Useful To Me
tongphlp Supreme	05-Aug-2026 14:18        tongphlp About Contact  Quote this Post!
x 0   x 0  Alert Admin	Loo u meant alexvar      ( Date: 05-Aug-2026 11:18) Posted: Loud whistle for the RMG management - Dr Lu and his children must wake up and smell the cofee! Enough shareholder value destruction!! time to stop and go for a strategic review! Dydd Joelton      ( Date: 29-Jul-2026 10:05) Posted: Analysts turn more cautious on Raffles Medical following softer 1HFY2026 Analysts have turned more cautious on Raffles Medical Group after its 1HFY2026 earnings, indicating a softer core Singapore market, even as its businesses in China has shown further improvement. RMG attributes the softer numbers to lower occupancy at its transitional care facilities, but the hospital services segment enjoyed 11% growth in profit before tax to $19.7 million, thanks to better efficiencies. RMG&rsquo s hospitals in China generated a 13% increase in revenue and its operating loss narrowed further. The insurance unit saw reduced losses too, driven by prudent claims adjudication and effective cost management. Roy Chen of UOB Kay Hian notes that RGM&rsquo s occupancy at the TCF has stabilised, the hospital in Singapore should see stable performance even with changes from the insurance regime, and the turnaround of the China hospitals should remain on track. Chen is of the view that RMG&rsquo s 1HFY2026 numbers have set a new baseline run rate, and as such has downgraded the stock from &ldquo buy&rdquo to &ldquo hold&rsquo along with a lower target price from $1.25 to 94 cents, which is based on 27.2x FY2027 earnings, pegged to 0.5 sd below RMG&rsquo s historical mean PE. RMG now trades at 26.6x FY2027 earnings, 0.6 sd below its historical mean PE, and largely in line with Asean peers averaging at 25.6x. Scroll to continue Chen expects RMG&rsquo s active share buyback programme to buy up to 100 million shares in FY2025 and FY2026 to limit further downside to its share price. Furthermore, Chen notes that RMG maintains a strong balance sheet and upbeat free cash flow generations. This gives it the flexibility to sustain a 3 cents per share dividend for the next few years, translating to a 3.3% yield. &ldquo 2026 marks RMG&rsquo s 50th year anniversary and we do not rule out the possibility of RMG paying a special dividend at the end of the year,&rdquo he adds. Eric Ong of Maybank Securities has kept his &ldquo buy&rdquo call. However, he has &ldquo conservatively&rdquo cut his FY2026 to FY2028 forecasts by 16-18% to factor in the slower run-rate and margins for RMG&rsquo s healthcare services. He has maintained his DCF-based valuation methodology and derived a new target price of $1.09, down from $1.20. Having said so, Ong also notes that RMG has fully repaid its bank loans of $51.1 million in the period. Even so, its balance sheet remains robust with net cash of $262.3 million, equivalent to 14 cents per share. &ldquo RMG can be more aggressive with its capital management, in our view,&rdquo says Ong. Similarly, Shekhar Jaiswal of RHB Bank Singapore has lowered his earnings forecast for this year by 14% for this year and 13 and 10% for FY2027 and FY2028 respectively, to take into account a lower TCF run-rate and slower insurance and China turnaround timeline. His new target price is now $1.15, from $1.30. Amanda Tan of DBS Group Research, also citing the weaker TCF operations, has trimmed her target price as well. From $1.25, she figures the stock is worth $1.20. &ldquo The Singapore core continues to provide a resilient, cash-generative earnings base. TCF utilisation is likely to remain a function of public hospital capacity additions and underlying healthcare demand. At current valuations and a dividend yield of 3%, we believe the risk-reward remains reasonable,&rdquo she says.
Useful To Me  Not Useful To Me
alexvar Senior	05-Aug-2026 11:18        alexvar About Contact  Quote this Post!
x 0   x 0  Alert Admin	Loud whistle for the RMG management - Dr Lu and his children must wake up and smell the cofee! Enough shareholder value destruction!! time to stop and go for a strategic review! Dydd Joelton      ( Date: 29-Jul-2026 10:05) Posted: Analysts turn more cautious on Raffles Medical following softer 1HFY2026 Analysts have turned more cautious on Raffles Medical Group after its 1HFY2026 earnings, indicating a softer core Singapore market, even as its businesses in China has shown further improvement. RMG attributes the softer numbers to lower occupancy at its transitional care facilities, but the hospital services segment enjoyed 11% growth in profit before tax to $19.7 million, thanks to better efficiencies. RMG&rsquo s hospitals in China generated a 13% increase in revenue and its operating loss narrowed further. The insurance unit saw reduced losses too, driven by prudent claims adjudication and effective cost management. Roy Chen of UOB Kay Hian notes that RGM&rsquo s occupancy at the TCF has stabilised, the hospital in Singapore should see stable performance even with changes from the insurance regime, and the turnaround of the China hospitals should remain on track. Chen is of the view that RMG&rsquo s 1HFY2026 numbers have set a new baseline run rate, and as such has downgraded the stock from &ldquo buy&rdquo to &ldquo hold&rsquo along with a lower target price from $1.25 to 94 cents, which is based on 27.2x FY2027 earnings, pegged to 0.5 sd below RMG&rsquo s historical mean PE. RMG now trades at 26.6x FY2027 earnings, 0.6 sd below its historical mean PE, and largely in line with Asean peers averaging at 25.6x. Scroll to continue Chen expects RMG&rsquo s active share buyback programme to buy up to 100 million shares in FY2025 and FY2026 to limit further downside to its share price. Furthermore, Chen notes that RMG maintains a strong balance sheet and upbeat free cash flow generations. This gives it the flexibility to sustain a 3 cents per share dividend for the next few years, translating to a 3.3% yield. &ldquo 2026 marks RMG&rsquo s 50th year anniversary and we do not rule out the possibility of RMG paying a special dividend at the end of the year,&rdquo he adds. Eric Ong of Maybank Securities has kept his &ldquo buy&rdquo call. However, he has &ldquo conservatively&rdquo cut his FY2026 to FY2028 forecasts by 16-18% to factor in the slower run-rate and margins for RMG&rsquo s healthcare services. He has maintained his DCF-based valuation methodology and derived a new target price of $1.09, down from $1.20. Having said so, Ong also notes that RMG has fully repaid its bank loans of $51.1 million in the period. Even so, its balance sheet remains robust with net cash of $262.3 million, equivalent to 14 cents per share. &ldquo RMG can be more aggressive with its capital management, in our view,&rdquo says Ong. Similarly, Shekhar Jaiswal of RHB Bank Singapore has lowered his earnings forecast for this year by 14% for this year and 13 and 10% for FY2027 and FY2028 respectively, to take into account a lower TCF run-rate and slower insurance and China turnaround timeline. His new target price is now $1.15, from $1.30. Amanda Tan of DBS Group Research, also citing the weaker TCF operations, has trimmed her target price as well. From $1.25, she figures the stock is worth $1.20. &ldquo The Singapore core continues to provide a resilient, cash-generative earnings base. TCF utilisation is likely to remain a function of public hospital capacity additions and underlying healthcare demand. At current valuations and a dividend yield of 3%, we believe the risk-reward remains reasonable,&rdquo she says.
Useful To Me  Not Useful To Me
Joelton Supreme	03-Aug-2026 09:10        Joelton About Contact  Quote this Post!
x 0   x 0  Alert Admin	Raffles Medical Group marks 50th anniversary Raffles Medical Group has marked its 50th anniversary, adding a milestone from the initial two-clinic practice to a regional healthcare group today that operates in 12 cities in five Asian countries. Besides its four hospitals, RMG runs over 100 multi-disciplinary clinics, offering services such as health screening, specialist care, diagnostic radiology, dental and traditional Chinese medicine. &ldquo When Dr Alfred Loh and I started a two-clinic practice, we simply wanted to care for our patients well. That conviction has remained at the heart of RafflesMedicalGroup through every moment that shaped us and every challenge we overcame," says executive chairman Dr Loo Choon Yong. " Our journey has been made possible by the dedication of our people, the trust of our patients and the support of our partners and communities," he adds. To mark this occasion, the company announced a five-year $5 million commitment to increase access to healthcare and education, advance healthy longevity research and support vulnerable communities. RMG will also award 50 scholarships over the next five years for students from Singapore and the region pursuing healthcare-related studies. The announcements were made at RMG&rsquo s 50th anniversary dinner, graced by President Tharman Shanmugaratnam, and Ong Ye Kung, Minister for Health and Coordinating Minister for Social Policies. According to RMG, the $5 million will focus on four priority areas: increasing access to healthcare, supporting education, advancing healthy longevity research, and uplifting vulnerable communities. One of the first initiatives under the commitment is a two-year partnership with Children&rsquo s Aid, formerly known as Children&rsquo s Aid Society. Over the next two years, RMG will partner CAL to make specialised care more accessible to children and youths who have experienced adverse life circumstances and are under the residential care of Melrose Home, with therapeutic and counselling services under Melrose Care, to support healing, healthy development and long-term well-being. Via the scholarship programme, RMG aims to develop healthcare talent across the cities in which it operates and nurture the next generation of professionals and leaders who will shape the future of healthcare. Since 2012, RMG has provided 51 scholarships to Singaporeans and others in the region.
Useful To Me  Not Useful To Me
Joelton Supreme	29-Jul-2026 10:05        Joelton About Contact  Quote this Post!
x 0   x 0  Alert Admin	Analysts turn more cautious on Raffles Medical following softer 1HFY2026 Analysts have turned more cautious on Raffles Medical Group after its 1HFY2026 earnings, indicating a softer core Singapore market, even as its businesses in China has shown further improvement. RMG attributes the softer numbers to lower occupancy at its transitional care facilities, but the hospital services segment enjoyed 11% growth in profit before tax to $19.7 million, thanks to better efficiencies. RMG&rsquo s hospitals in China generated a 13% increase in revenue and its operating loss narrowed further. The insurance unit saw reduced losses too, driven by prudent claims adjudication and effective cost management. Roy Chen of UOB Kay Hian notes that RGM&rsquo s occupancy at the TCF has stabilised, the hospital in Singapore should see stable performance even with changes from the insurance regime, and the turnaround of the China hospitals should remain on track. Chen is of the view that RMG&rsquo s 1HFY2026 numbers have set a new baseline run rate, and as such has downgraded the stock from &ldquo buy&rdquo to &ldquo hold&rsquo along with a lower target price from $1.25 to 94 cents, which is based on 27.2x FY2027 earnings, pegged to 0.5 sd below RMG&rsquo s historical mean PE. RMG now trades at 26.6x FY2027 earnings, 0.6 sd below its historical mean PE, and largely in line with Asean peers averaging at 25.6x. Scroll to continue Chen expects RMG&rsquo s active share buyback programme to buy up to 100 million shares in FY2025 and FY2026 to limit further downside to its share price. Furthermore, Chen notes that RMG maintains a strong balance sheet and upbeat free cash flow generations. This gives it the flexibility to sustain a 3 cents per share dividend for the next few years, translating to a 3.3% yield. &ldquo 2026 marks RMG&rsquo s 50th year anniversary and we do not rule out the possibility of RMG paying a special dividend at the end of the year,&rdquo he adds. Eric Ong of Maybank Securities has kept his &ldquo buy&rdquo call. However, he has &ldquo conservatively&rdquo cut his FY2026 to FY2028 forecasts by 16-18% to factor in the slower run-rate and margins for RMG&rsquo s healthcare services. He has maintained his DCF-based valuation methodology and derived a new target price of $1.09, down from $1.20. Having said so, Ong also notes that RMG has fully repaid its bank loans of $51.1 million in the period. Even so, its balance sheet remains robust with net cash of $262.3 million, equivalent to 14 cents per share. &ldquo RMG can be more aggressive with its capital management, in our view,&rdquo says Ong. Similarly, Shekhar Jaiswal of RHB Bank Singapore has lowered his earnings forecast for this year by 14% for this year and 13 and 10% for FY2027 and FY2028 respectively, to take into account a lower TCF run-rate and slower insurance and China turnaround timeline. His new target price is now $1.15, from $1.30. Amanda Tan of DBS Group Research, also citing the weaker TCF operations, has trimmed her target price as well. From $1.25, she figures the stock is worth $1.20. &ldquo The Singapore core continues to provide a resilient, cash-generative earnings base. TCF utilisation is likely to remain a function of public hospital capacity additions and underlying healthcare demand. At current valuations and a dividend yield of 3%, we believe the risk-reward remains reasonable,&rdquo she says.
Useful To Me  Not Useful To Me
Nippon72 Veteran	29-Jul-2026 07:25        Nippon72 About Contact  Quote this Post! Style: Fundamental   Mood: Yells: "Dude, is ALWAYS Time in the market than Timing the market! "
x 0   x 0  Alert Admin	We should all understand how Chinese works or their psyche?! If you are there to " fleece" them, you reminded them of the century humiliation. They will turnaround & gobble you up. Just like SIP. If you are there to collaborate, ride on their coattails, and they gain more than you, say eg 60/40 profits -  then they are ok to work with you.  I read with interests how RMG workaround this with their institutes collaboration/exchange.  Singapore market being small we got to expand out earn less with the 40% or dun even have this 40% to begin with?  China is ageing fast especially with longevity and smaller household, medical care is inevitable. RMG will be able to have a slice of this pie. In a real world is a question who needs who more.  Vested, becos I am also ageing fast.
Useful To Me  Not Useful To Me
alexvar Senior	28-Jul-2026 15:52        alexvar About Contact  Quote this Post!
x 0   x 0  Alert Admin	The china market is a perennial issue for Dr Lu - losings hundreds of millions of shareholder value in the China market since the 2010s.
Useful To Me  Not Useful To Me
Cadence88 Veteran	28-Jul-2026 14:50        Cadence88 About Contact  Quote this Post!
x 0   x 0  Alert Admin	It looks like the problem is from the transitional care facilities (gov contract).. alexvar      ( Date: 28-Jul-2026 14:35) Posted: the profits are dropping, operating cash inflows are dropping, and Raffles med continues to lose money in China ! hopeless until Dr Lu changes his opinion about China endless money pit, and focuses on the profitable growth. dydd
Useful To Me  Not Useful To Me
alexvar Senior	28-Jul-2026 14:35        alexvar About Contact  Quote this Post!
x 0   x 0  Alert Admin	the profits are dropping, operating cash inflows are dropping, and Raffles med continues to lose money in China ! hopeless until Dr Lu changes his opinion about China endless money pit, and focuses on the profitable growth. dydd
Useful To Me  Not Useful To Me
Joelton Supreme	28-Jul-2026 09:28        Joelton About Contact  Quote this Post!
x 0   x 0  Alert Admin	Raffles Medical posts 1HFY2026 earnings of $29.0 mil, down 9.6% y-o-y Raffles Medical Group posted a 9.6% decrease in its 1HFY2026 ended June profit after tax and minority interests (Patmi), down to $29.0 million from $32.1 million in 1HFY2025. The lower earnings came from softer contributions from the healthcare services division and Raffles Health Insurance (RHI), even as the hospital services division posted improved profitability. Revenue in the same period fell 6.7% y-o-y to $353.2 million, weighed down by lower occupancy at transitional care facilities and reduced insurance revenue, though this was partially cushioned by continued growth in its China operations. In the half year, the hospital services division was the standout performer, with profit rising 11.0% to $19.7 million from $17.7 million in 1HFY2025. RMG explains that the better numbers came from &ldquo improved operational efficiency and cost management&rdquo across both Singapore and China hospitals, which lifted the division&rsquo s profit margin from 10.2% in 1HFY2025 to 11.6% in 1HFY2026. On the other hand, the healthcare services division generated revenue of $119.5 million, down 16.0% y-o-y, mainly due to lower occupancy at transitional care facilities. Profit for the division fell correspondingly to $15.6 million from $24.9 million. Raffles China Healthcare continued to gain traction, with revenue climbing 13.0% to RMB184.8 million ($35.2 million) in 1H2026, from RMB163.6 million in 1H2025. RMG says it has strengthened its brand among patients in China, with earlier cost-optimisation initiatives further supporting the improved financial performance. RHI recorded revenue of $88.5 million, down from $94.9 million a year earlier. Even so, its operating loss narrowed 64.3% to $1.1 million from $3.1 million, closer to breakeven, thanks to prudent claims adjudication and effective cost management. In her July 27 note, Amanda Tan of DBS Group Research expects insurance profitability to improve further following increases in insurance premiums, which took effect from April 1. &ldquo The higher premium rates should help offset medical inflation and rising claims costs over time, although the pace of earnings recovery will depend on underwriting discipline and claims ratios,&rdquo she adds. The group generated operating cash flow of $64.6 million in 1HFY2026, up from $56.6 million in 1HFY2025. As at end June 2026, the group&rsquo s cash position stood at $262.3 million, down from $310.8 million at end-2025, after it paid out $55.2 million in dividends and repaid $51.1 million in bank loans during the period. Based on current conditions and barring unforeseen circumstances, the board expects the group to remain profitable in FY2026. The results come as RMG marks its 50th anniversary, having crossed the milestone of 50 million cumulative patient visits on 23 July 2026. &ldquo Reaching 50 million patient visits in our 50th anniversary year is a meaningful reflection of the trust that generations of patients and their families have placed in us, and the dedication of our people,&rdquo says executive chairman Dr Loo Choon Yong. &ldquo As we look towards Raffles 100, we will build on this legacy, deepen our capabilities across Asia and continue caring for generations to come,&rdquo he adds. As at 11.32am, shares in Raffles Medical were trading at 91 cents, down 4.21% or 4 cents.
Useful To Me  Not Useful To Me
Joelton Supreme	27-Jul-2026 09:36        Joelton About Contact  Quote this Post!
x 0   x 0  Alert Admin	Raffles Medical H1 profit falls 9.6% to S$29 million [SINGAPORE] Raffles Medical Group : BSL -0.52% posted a net profit of S$29 million for its first half ended Jun 30, down 9.6 per cent from S$32.1 million in the same period a year prior. The healthcare group crossed the milestone of 50 million cumulative patient visits on Jul 23 across its integrated healthcare network in its 50th year, it said on Monday (Jul 27). In the China market, revenue increased 13 per cent to 184.8 million yuan (US$27.2 million) in H1 FY2026 from 163.6 million yuan in H1 FY2025. Prior cost-optimisation initiatives also contributed to improved financial performance, it aded. Overall revenue decreased 6.7 per cent year on year to S$353.2 million from S$378.4 million. Its healthcare services division reported a 16 per cent decline in revenue to S$119.5 million and a profit of S$15.6 million, mainly due to lower occupancy at transitional care facilities. Meanwhile, the group&rsquo s hospital services division registered revenue of S$170.2 million and an 11 per cent increase in profit to S$19.7 million. This was driven by improved operational efficiency and cost management across hospitals in Singapore and China. Revenue of Raffles Health Insurance stood at S$88.5 million and incurred an operating loss of S$1.1 million, narrowing by 64.3 per cent from S$3.1 million in the year prior. This was due to better claims experience, prudent claims adjudication and effective cost management. Diluted earnings per share for the period stood at S$0.0157, down from S$0.0173 in the previous corresponding period. No interim dividend was declared by the mainboard-listed group. Operating cash flow generated by the group stood at S$64.6 million in H1 FY2026. Dividends totalling S$55.2 million were distributed, and the group fully repaid bank loans amounting to S$51.1 million. Cash and cash equivalents stood at S$262.3 million as at Jun 30, providing flexibility to support existing operations and pursue disciplined growth opportunities. Based on current conditions and barring unforeseen circumstances, the board expects the medical group to remain profitable in FY2026. The group noted that the global economic outlook remains uncertain amid ongoing geopolitical tensions, evolving trade disputes and volatility in financial markets. While these factors may affect business confidence, the demand for quality healthcare services is expected to remain resilient. The healthcare player added that it remains committed to strengthening its regional healthcare network by broadening its range of clinical services, enhancing specialist capabilities and expanding access to quality healthcare across the Asian cities in which it operates. The group will also continue to evaluate and adopt appropriate technologies, including artificial intelligence, to improve operational efficiency, enhance service excellence and support the delivery of safe, high-quality healthcare services. Shares of Raffles Medical fell 0.5 per cent to close S$0.005 lower at S$0.95 on Friday.
Useful To Me  Not Useful To Me
spursfan Supreme	27-Jul-2026 08:40        spursfan About Contact  Quote this Post!
x 0   x 0  Alert Admin	https://links.sgx.com/1.0.0/corporate-announcements/9K99JD5B2MV11N5S/897355_RafflesMedicalGroup_Media_Release_1H2026_Result_Announcement_27Jul2026.pdf
Useful To Me  Not Useful To Me
Joelton Supreme	11-Jul-2026 14:02        Joelton About Contact  Quote this Post!
x 0   x 0  Alert Admin	RHB remains upbeat on Raffles Medical&rsquo s growth story, cites insurance unit as &lsquo overlooked&rsquo catalyst The healthcare sector is always in the news for one reason or another. Just this week, Foundation Healthcare became the latest healthcare play to be listed on the Singapore Exchange. Raising some $242 million and giving it a market cap of around $1 billion, Foundation Healthcare is said to be the largest healthcare listing since IHH Healthcare&rsquo s 2012 debut. Foundation Healthcare is newer, and IHH Healthcare is larger, but Raffles Medical Group, another leading healthcare stock listed on the Singapore Exchange, has been on investors&rsquo radar since its 1997 listing. Raffles Medical, which marks its 50th anniversary this year under the leadership of executive chairman Dr Loo Choon Yong, started as two clinics back in 1976. From just two clinics, the company has grown to operate in 14 cities across five countries, including three hospitals in China. &ldquo Look after patients properly, and the business will look after itself,&rdquo says Dr Loo. Healthcare stocks are generally favoured as structural growth stories. &ldquo The globally ageing population theme, which Singapore is also experiencing, will also see higher demand for healthcare services and products, and this in turn will benefit several of the healthcare providers listed on the Singapore market,&rdquo says OCBC Group Research. However, as investors here would observe, healthcare stocks here, including Raffles Medical, have their ups and downs. For one, during the thick of the pandemic, the likes of Raffles Medical were drafted to provide additional services, and earnings spiked over those couple of years as a result. In what is supposed to be the post-pandemic normalisation phase, investors&rsquo attention was then drawn to costs incurred by Raffles Medical to get its hospitals in China up and running. Raffles Medical&rsquo s share price, since its recent peak of $1.07 in February, has dropped more than 13% as investors ponder its slowing growth. Yet, from the perspective of Shekhar Jaiswal of RHB Bank Singapore, this recent de-rating is &ldquo an attractive entry point&rdquo ahead of the company&rsquo s 1HFY2026 earnings to be reported later this month. Specifically, Jaiswal will be looking for better data points on whether Raffles Medical remains on track to achieve its ebitda breakeven target for at least one China hospital by the end of this year, and if the new Integrated Shield Plan rider regulations will be structurally positive for its insurance unit, Raffles Health Insurance. Meanwhile, Jaiswal, who has kept his &ldquo buy&rdquo call and $1.30 target price, notes that Raffles Medical trades at a discount to its Asean healthcare peers despite strong earnings visibility. Besides its home market of Singapore, Raffles Medical has bet big on China, which now accounts for 31% of its non-current assets but contributes just 9% of total revenue, underscoring opportunities to improve asset productivity. Jaiswal points out that its Beijing hospital is already profitable, while Shanghai and Chongqing remain in the ramp-up phase. Raffles Medical, according to the analyst, has expanded its addressable market beyond expatriates to include China&rsquo s affluent domestic population, the top 30% of consumers seeking premium healthcare. &ldquo With a target for at least one China hospital to achieve ebitda breakeven by the end of 2026, 1HFY2026 results should provide a key read-through on revenue growth and narrowing operating losses,&rdquo says Jaiswal. Here in Singapore, the healthcare industry is seeing changes from reforms to the insurance system, with effect from April 1, forming what Jaiswal calls &ldquo an overlooked earnings catalyst&rdquo . &ldquo We believe the market underestimates the earnings upside from the Ministry of Health&rsquo s Integrated Shield Plan rider reforms for Raffles Health Insurance,&rdquo says Jaiswal. As it is, losses have already narrowed materially through stronger claims discipline, with the business approaching breakeven in 2HFY2025. Jaiswal believes that the reforms should structurally improve industry claims ratios through higher patient co-payments, broader insurance affordability and support premium growth and operating leverage. The new policies aim to curb steep premium increases but also impose a higher share of out-of-pocket costs on patients, thereby tempering demand for private hospital care. However, Jaiswal believes there will be limited impact on Raffles Medical&rsquo s Singapore hospital operations given its extensive insurer panel, demand driven by genuine medical needs, and transitional grandfathering provisions, under which existing riders remain unaffected until policy renewals after April 1, 2028. &ldquo This should allow any demand adjustment to occur gradually, while Raffles Medical could also gain panel share as insurers increasingly favour cost-efficient providers,&rdquo he adds. Meanwhile, Raffles Medical can choose to flex its balance sheet, with options ranging from overseas acquisitions to further share buybacks to maintaining dividend payouts. &ldquo The debate is not financial capacity but capital allocation discipline. Investors may favour buybacks and dividends unless it can demonstrate that regional expansion, including potential opportunities in Vietnam, is earnings-accretive and avoids the prolonged gestation seen in China,&rdquo says Jaiswal.
Useful To Me  Not Useful To Me
piscesmonkey Supreme	08-Jul-2026 12:01        piscesmonkey About Contact  Quote this Post!
x 0   x 0  Alert Admin	Broker come alway drop more dont know why Joelton      ( Date: 08-Jul-2026 11:31) Posted: RHB calls recent drop in Raffles Medical shares an ' attractive' entry point Raffles Medical' s share price, since its recent peak of $1.07 in February, has dropped more than 13% since. From the perspective of Shekhar Jaiswal of RHB Bank Singapore, this recent de-rating is " an attractive entry point" ahead of the company' s 1HFY2026 earnings to be reported later this month. Specifically, Jaiswal will be looking for better data points on whether Raffles Medical remains on track to achieve its EBITDA breakeven target for at least one China hospital by the end of this year, and if the new Integrated Shield Plan rider regulations will be structurally positive for its insurance unit, Raffles Health Insurance. Meanwhile, Jaiswal, who has kept his " buy" call and $1.30 target price, notes that Raffles Medical trades at a discount to its ASEAN healthcare peers despite strong earnings visibility. Besides home market Singapore, Raffles Medical has bet big on China, which now accounts for 31% of its non-current assets but contributes just 9% of the total revenue, underscoring that asset productivity can be improved. Jaiswal points out that its Beijing hospital is already profitable, while Shanghai and Chongqing remain in the ramp-up phase. Raffles Medical, according to the analyst, has expanded its addressable market beyond expatriates to also China' s affluent domestic population, which is the top 30% of consumers seeking premium healthcare. " With a target for at least one China hospital to achieve ebitda breakeven by the end 2026, 1HFY2026 results should provide a key read-through on revenue growth and narrowing operating losses," says Jaiswal. Here in Singapore, the healthcare industry is seeing some changes from reforms made to the insurance system with effect from April 1, forming what Jaiswal calls " an overlooked earnings catalyst" . " We believe the market underestimates the earnings upside from the Ministry of Health' s Integrated Shield Plan rider reforms for Raffles Health Insurance," says Jaiswal. As it is, losses have already narrowed materially through stronger claims discipline, with the business approaching breakeven in 2HFY2025. Jaiswal believes that the reforms should structurally improve industry claims ratios via higher patient co-payments while broadening insurance affordability, and supporting premium growth and operating leverage. Broadly, the new policies are to help curb the steep jumps in premiums, but also impose a higher proportion of out-of-pocket costs for patients, and could thereby temper private hospital demand. However, Jaiswal believes there will be limited impact on Raffles Medical&rsquo s Singapore hospital operations given its extensive insurer panel, demand driven by genuine medical needs, and transitional grandfathering provisions, under which existing riders remain unaffected until policy renewals after Apr 1 2028. " This should allow any demand adjustment to occur gradually, while RFMD could also gain panel share as insurers increasingly favour cost-efficient providers," he adds. Meanwhile, Raffles Medical can choose to flex its balance sheet, with options ranging from overseas acquisitions, further share buybacks and maintaining dividend payouts. " The debate is not financial capacity but capital allocation discipline. Investors may favour buybacks and dividends unless it can demonstrate that regional expansion, including potential opportunities in Vietnam, is earnings-accretive and avoids the prolonged gestation seen in China," says Jaiswal. Raffles Medical shares traded at 93 cents as at 10.01 am, up 0.54%.
Useful To Me  Not Useful To Me
Joelton Supreme	08-Jul-2026 11:31        Joelton About Contact  Quote this Post!
x 0   x 0  Alert Admin	RHB calls recent drop in Raffles Medical shares an ' attractive' entry point Raffles Medical' s share price, since its recent peak of $1.07 in February, has dropped more than 13% since. From the perspective of Shekhar Jaiswal of RHB Bank Singapore, this recent de-rating is " an attractive entry point" ahead of the company' s 1HFY2026 earnings to be reported later this month. Specifically, Jaiswal will be looking for better data points on whether Raffles Medical remains on track to achieve its EBITDA breakeven target for at least one China hospital by the end of this year, and if the new Integrated Shield Plan rider regulations will be structurally positive for its insurance unit, Raffles Health Insurance. Meanwhile, Jaiswal, who has kept his " buy" call and $1.30 target price, notes that Raffles Medical trades at a discount to its ASEAN healthcare peers despite strong earnings visibility. Besides home market Singapore, Raffles Medical has bet big on China, which now accounts for 31% of its non-current assets but contributes just 9% of the total revenue, underscoring that asset productivity can be improved. Jaiswal points out that its Beijing hospital is already profitable, while Shanghai and Chongqing remain in the ramp-up phase. Raffles Medical, according to the analyst, has expanded its addressable market beyond expatriates to also China' s affluent domestic population, which is the top 30% of consumers seeking premium healthcare. " With a target for at least one China hospital to achieve ebitda breakeven by the end 2026, 1HFY2026 results should provide a key read-through on revenue growth and narrowing operating losses," says Jaiswal. Here in Singapore, the healthcare industry is seeing some changes from reforms made to the insurance system with effect from April 1, forming what Jaiswal calls " an overlooked earnings catalyst" . " We believe the market underestimates the earnings upside from the Ministry of Health' s Integrated Shield Plan rider reforms for Raffles Health Insurance," says Jaiswal. As it is, losses have already narrowed materially through stronger claims discipline, with the business approaching breakeven in 2HFY2025. Jaiswal believes that the reforms should structurally improve industry claims ratios via higher patient co-payments while broadening insurance affordability, and supporting premium growth and operating leverage. Broadly, the new policies are to help curb the steep jumps in premiums, but also impose a higher proportion of out-of-pocket costs for patients, and could thereby temper private hospital demand. However, Jaiswal believes there will be limited impact on Raffles Medical&rsquo s Singapore hospital operations given its extensive insurer panel, demand driven by genuine medical needs, and transitional grandfathering provisions, under which existing riders remain unaffected until policy renewals after Apr 1 2028. " This should allow any demand adjustment to occur gradually, while RFMD could also gain panel share as insurers increasingly favour cost-efficient providers," he adds. Meanwhile, Raffles Medical can choose to flex its balance sheet, with options ranging from overseas acquisitions, further share buybacks and maintaining dividend payouts. " The debate is not financial capacity but capital allocation discipline. Investors may favour buybacks and dividends unless it can demonstrate that regional expansion, including potential opportunities in Vietnam, is earnings-accretive and avoids the prolonged gestation seen in China," says Jaiswal. Raffles Medical shares traded at 93 cents as at 10.01 am, up 0.54%.
Useful To Me  Not Useful To Me
tongphlp Supreme	02-Jul-2026 06:49        tongphlp About Contact  Quote this Post!
x 0   x 0  Alert Admin	no prob! he has tonnes of $ alexvar      ( Date: 18-May-2026 09:56) Posted: china market losses since the 2010s is destroying RMG share price. Dr Lu is stubborn or maybe happless about non-existing growth in the stagnant China market. Look and learn from IHH and its profitable growth! dont be stubborn, like a mule. dydd
Useful To Me  Not Useful To Me
tongphlp Supreme	01-Jul-2026 13:46        tongphlp About Contact  Quote this Post!
x 0   x 0  Alert Admin	meant he lost $$...wrong judgement? MambaFinancial89      ( Date: 26-Jun-2026 15:53) Posted: Chairman Loo last bought shares at $0.95 on 19/5/26 (522,000 shares). Hope to see him averaging down at lower levels if he is indeed so confident.
Useful To Me  Not Useful To Me
piscesmonkey Supreme	01-Jul-2026 09:48        piscesmonkey About Contact  Quote this Post!
x 0   x 0  Alert Admin	Overover sold soon strong rebound
Useful To Me  Not Useful To Me
MambaFinancial89 Veteran	26-Jun-2026 15:53        MambaFinancial89 About Contact  Quote this Post! Style: Fundamental   Yells: "Be greedy when others are fearful. "
x 0   x 0  Alert Admin	Chairman Loo last bought shares at $0.95 on 19/5/26 (522,000 shares). Hope to see him averaging down at lower levels if he is indeed so confident.
Useful To Me  Not Useful To Me
alexvar Senior	18-May-2026 09:56        alexvar About Contact  Quote this Post!
x 0   x 0  Alert Admin	china market losses since the 2010s is destroying RMG share price. Dr Lu is stubborn or maybe happless about non-existing growth in the stagnant China market. Look and learn from IHH and its profitable growth! dont be stubborn, like a mule. dydd
Useful To Me  Not Useful To Me

                                                         First   1-20 of 47   Older>   Last